吉西他滨联合奈达铂及尼妥珠单抗治疗晚期鼻咽癌的疗效分析

Research on Gemcitabine and Nedaplatin Combined with Nimotuzumab in the Treatment for Advanced Nasopharyngeal Carcinoma

目的:观察吉西他滨联合奈达铂及尼妥珠单抗治疗晚期鼻咽癌的疗效和安全性。方法:选择2010年1月至2012年1月在我院住院治疗的98例晚期鼻咽癌患者为研究对象,运用随机数字表法将符合本研究纳入标准和排除标准的患者分为A组和B组,A组患者给予吉西他滨联合奈达铂治疗,而B组患者则给予吉西他滨联合奈达铂及尼妥珠单抗治疗,比较两组患者的临床疗效和安全性。结果:B组患者治疗总有效率(73.47%)明显高于A组患者治疗总有效率(51.02%),差异有统计学意义(P<0.05),而B组的药物毒副反应并未较A组患者的明显增加(P>0.05)。结论:吉西他滨联合奈达铂及尼妥珠单抗治疗晚期鼻咽癌疗效确切,安全高效,毒副反应少,值得推广。

Objective ： To investigate the clinical efficacy and safety of gemcitabine and nedaplatin com bined with nimotuznmab in the treatment for advanced nasopharyngeal carcinoma. Method： The clinical data of ninetyeight patients with advanced nasopharyngeal carcinoma who were treated in our hospital from Janu ary 2010 to January 2012 were collected, then patients with advanced nasopharyngeal carcinoma were divided into group A and group B by using a random number table, patients with advanced nasopharyngeal carcinomain group A was given nedaplatin and nedaplatin, but patients with advanced nasopharyngeal carcinoma in group B was also given nedaplatin and nedaplatin combined with nimotuzumab, the clinical efficacy and ad verse drug reaction of each group was evaluated. Result： The clinical efficacy was higher in group B than that in group A （73.47% vs 51.02% ） ,and the rate of adverse drug reaction was no different in two groups （ P〉 0. 05 ）. Conclusion ： The clinical efficacy and safety of nedaplatin and nedaplatin combined with nimotuzum ab in the treatment for＇advanced nasopharyngeal carcinoma can obtane satisfactory curative effect,it is safe and reliable, and it is worthy of clinical application.